$55.3 Million is the total value of Opus Point Partners Management, LLC's 55 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 19.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IBB | ISHARES TRnasdaq biotech | $12,438,000 | -8.8% | 125,000 | 0.0% | 22.48% | +11.4% | |
| IBB | ISHARES TRcall | $8,458,000 | -8.8% | 85,000 | 0.0% | 15.28% | +11.4% | |
| LABU | Buy | DIREXION SHS ETF TRsp biotch bl new | $3,086,000 | -37.5% | 99,855 | +1.4% | 5.58% | -23.7% |
| MTD | METTLER TOLEDO INTERNATIONAL | $2,279,000 | -16.1% | 3,235 | 0.0% | 4.12% | +2.4% | |
| BMY | BRISTOL MYERS SQUIBB CO | $1,673,000 | +11.8% | 33,000 | 0.0% | 3.02% | +36.5% | |
| SGEN | Buy | SEATTLE GENETICS INC | $1,539,000 | +24.2% | 18,020 | +0.7% | 2.78% | +51.7% |
| ILMN | Buy | ILLUMINA INC | $1,436,000 | -17.0% | 4,721 | +0.5% | 2.60% | +1.4% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $1,403,000 | -6.6% | 8,279 | +1.0% | 2.54% | +14.1% |
| IONS | IONIS PHARMACEUTICALS INC | $1,206,000 | -6.7% | 20,124 | 0.0% | 2.18% | +13.9% | |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $1,100,000 | +13.5% | 13,684 | +2.5% | 1.99% | +38.6% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $973,000 | -25.2% | 9,933 | +0.1% | 1.76% | -8.6% |
| QGEN | QIAGEN NV | $951,000 | -18.7% | 28,858 | 0.0% | 1.72% | -0.7% | |
| ONCE | SPARK THERAPEUTICS INC | $941,000 | -5.2% | 9,699 | 0.0% | 1.70% | +15.7% | |
| FBIO | Buy | FORTRESS BIOTECH INC | $865,000 | +146.4% | 613,551 | +162.2% | 1.56% | +201.2% |
| PRQR | PROQR THRAPEUTICS N V | $798,000 | -36.7% | 138,461 | 0.0% | 1.44% | -22.6% | |
| INCY | Buy | INCYTE CORP | $791,000 | -12.3% | 10,659 | +0.4% | 1.43% | +7.0% |
| EXAS | EXACT SCIENCES CORP | $771,000 | -23.4% | 8,534 | 0.0% | 1.39% | -6.5% | |
| REGN | Buy | REGENERON PHARMACEUTICALS | $677,000 | -2.6% | 2,439 | +9.8% | 1.22% | +19.0% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $654,000 | -18.8% | 9,700 | +3.2% | 1.18% | -0.8% |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $632,000 | +50.5% | 18,631 | 0.0% | 1.14% | +83.9% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $596,000 | -16.4% | 6,190 | 0.0% | 1.08% | +2.1% | |
| QURE | UNIQURE NV | $560,000 | -49.6% | 14,215 | 0.0% | 1.01% | -38.4% | |
| CELG | CELGENE CORP | $559,000 | +7.5% | 5,625 | 0.0% | 1.01% | +31.3% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $542,000 | -12.9% | 13,214 | 0.0% | 0.98% | +6.4% | |
| EPZM | EPIZYME INC | $520,000 | -17.7% | 50,378 | 0.0% | 0.94% | +0.5% | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $510,000 | +57.9% | 33,641 | +102.2% | 0.92% | +92.9% |
| BPMC | BLUEPRINT MEDICINES CORP | $498,000 | -22.2% | 6,780 | 0.0% | 0.90% | -5.0% | |
| BOLD | AUDENTES THERAPEUTICS INC | $487,000 | -25.8% | 17,339 | 0.0% | 0.88% | -9.4% | |
| GTHX | G1 THERAPEUTICS INC | $475,000 | -25.7% | 20,844 | 0.0% | 0.86% | -9.2% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $460,000 | -7.8% | 9,479 | 0.0% | 0.83% | +12.6% | |
| BHVN | BIOHAVEN PHARMACTL HLDG CO L | $453,000 | -4.6% | 10,852 | 0.0% | 0.82% | +16.5% | |
| ARNA | ARENA PHARMACEUTICALS INC | $447,000 | -22.0% | 9,770 | 0.0% | 0.81% | -4.7% | |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $432,000 | +35.0% | 12,005 | +0.2% | 0.78% | +65.1% |
| GWPH | GW PHARMACEUTICALS PLCads | $423,000 | -33.2% | 3,674 | 0.0% | 0.76% | -18.5% | |
| ZGNX | ZOGENIX INC | $389,000 | -16.3% | 9,725 | 0.0% | 0.70% | +2.2% | |
| MGNX | MACROGENICS INC | $384,000 | -24.7% | 30,075 | 0.0% | 0.69% | -8.1% | |
| NTLA | INTELLIA THERAPEUTICS INC | $380,000 | -18.5% | 28,490 | 0.0% | 0.69% | -0.3% | |
| TECH | BIO TECHNE CORP | $303,000 | -6.2% | 1,551 | 0.0% | 0.55% | +14.6% | |
| IQV | IQVIA HLDGS INC | $297,000 | -6.9% | 1,985 | 0.0% | 0.54% | +13.8% | |
| AMGN | Buy | AMGEN INC | $294,000 | +14.4% | 1,518 | +8.7% | 0.53% | +39.7% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $282,000 | +11.0% | 3,127 | +3.8% | 0.51% | +35.6% |
| CKPT | CHECKPOINT THERAPEUTICS INC | $281,000 | -17.8% | 112,760 | 0.0% | 0.51% | +0.4% | |
| CRL | CHARLES RIV LABS INTL INC | $280,000 | -6.7% | 2,112 | 0.0% | 0.51% | +14.0% | |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $279,000 | – | 3,498 | +100.0% | 0.50% | – |
| GRFS | GRIFOLS S Asp adr rep b nvt | $264,000 | -5.0% | 13,196 | 0.0% | 0.48% | +16.1% | |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $261,000 | -44.1% | 3,926 | -33.1% | 0.47% | -31.7% |
| BIIB | BIOGEN INC | $261,000 | -0.8% | 1,123 | 0.0% | 0.47% | +21.3% | |
| GILD | GILEAD SCIENCES INC | $259,000 | -6.2% | 4,082 | 0.0% | 0.47% | +14.7% | |
| LGND | Buy | LIGAND PHARMACEUTICALS INC | $242,000 | +0.4% | 2,428 | +15.0% | 0.44% | +22.4% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $235,000 | -47.2% | 12,927 | +3.4% | 0.42% | -35.4% |
| EXEL | Buy | EXELIXIS INC | $232,000 | -4.9% | 13,132 | +14.8% | 0.42% | +16.1% |
| ALKS | New | ALKERMES PLC | $227,000 | – | 11,632 | +100.0% | 0.41% | – |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $217,000 | -32.6% | 5,064 | 0.0% | 0.39% | -17.6% | |
| FGEN | Buy | FIBROGEN INC | $212,000 | -4.1% | 5,742 | +17.6% | 0.38% | +17.1% |
| REPH | RECRO PHARMA INC | $126,000 | +9.6% | 11,353 | 0.0% | 0.23% | +34.1% | |
| AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -4,806 | -100.0% | -0.36% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -6,116 | -100.0% | -0.51% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -3,570 | -100.0% | -0.55% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -48,485 | -100.0% | -0.60% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -36,731 | -100.0% | -0.68% | – |
| PCRX | Exit | PACIRA BIOSCIENCES | $0 | – | -11,250 | -100.0% | -0.72% | – |
| INSM | Exit | INSMED INC | $0 | – | -26,936 | -100.0% | -1.02% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -5,840 | -100.0% | -1.10% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -5,353 | -100.0% | -1.20% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -62,575 | -100.0% | -1.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.